Kerstin Rhiem

11PUBLICATIONS
75CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsOncology and carcinogenesis not elsewhere classifiedPredictive and prognostic markersRehabilitation engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Feb 25, 2025
Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study.

Peter A Fasching, Sabine Schmatloch, Jan Hauke

|Nov 22, 2024
Calculating Future 10-Year Breast Cancer Risks in Risk-Adapted Surveillance: A Method Comparison and Application in Clinical Practice.

Silke Zachariae, Anne S Quante, Marion Kiechle

|Sep 19, 2023
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.

Theresa Link, Jens-Uwe Blohmer, Wolfgang D Schmitt

|May 15, 2023
Assessing Psychological Morbidity in Cancer-Unaffected BRCA1/2 Pathogenic Variant Carriers: A Systematic Review.

Anna Isselhard, Zoë Lautz, Kerstin Rhiem

|May 13, 2023
Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients.

Majdi Imterat, Philipp Harter, Kerstin Rhiem

|Feb 11, 2023
Coping Self-Efficacy and Its Relationship with Psychological Morbidity after Genetic Test Result Disclosure: Results from Cancer-Unaffected BRCA1/2 Mutation Carriers.

Anna Isselhard, Zoe Lautz, Maren Töpper

Pageof 2

Frequent Collaborators

4 joint publications

Beyhan Ataseven

3 joint publications

Jens-Uwe Blohmer

3 joint publications

Peter A Fasching

2 joint publications

Theresa Link